138 related articles for article (PubMed ID: 38840665)
1. Targeting of wnt signalling pathway by small bioactive molecules for the treatment of Alzheimer's disease.
Dutta A; Bhattacharya P; Chutia P; Borah A
In Silico Pharmacol; 2024; 12(1):50. PubMed ID: 38840665
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics and structure-based virtual screening and identification of natural compounds as Wnt signaling modulators: possible therapeutics for Alzheimer's disease.
Manandhar S; Sankhe R; Priya K; Hari G; Kumar B H; Mehta CH; Nayak UY; Pai KSR
Mol Divers; 2022 Oct; 26(5):2793-2811. PubMed ID: 35146638
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model.
Martin Flores N; Podpolny M; McLeod F; Workman I; Crawford K; Ivanov D; Leonenko G; Escott-Price V; Salinas PC
Elife; 2024 Jan; 12():. PubMed ID: 38285009
[TBL] [Abstract][Full Text] [Related]
4. Activation of Wnt/β-catenin pathway mitigates blood-brain barrier dysfunction in Alzheimer's disease.
Wang Q; Huang X; Su Y; Yin G; Wang S; Yu B; Li H; Qi J; Chen H; Zeng W; Zhang K; Verkhratsky A; Niu J; Yi C
Brain; 2022 Dec; 145(12):4474-4488. PubMed ID: 35788280
[TBL] [Abstract][Full Text] [Related]
5. Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease.
Menet R; Bourassa P; Calon F; ElAli A
Neurochem Int; 2020 Dec; 141():104881. PubMed ID: 33068684
[TBL] [Abstract][Full Text] [Related]
6. A role for APP in Wnt signalling links synapse loss with β-amyloid production.
Elliott C; Rojo AI; Ribe E; Broadstock M; Xia W; Morin P; Semenov M; Baillie G; Cuadrado A; Al-Shawi R; Ballard CG; Simons P; Killick R
Transl Psychiatry; 2018 Sep; 8(1):179. PubMed ID: 30232325
[TBL] [Abstract][Full Text] [Related]
7. Cyanidin Ameliorates Bisphenol A-Induced Alzheimer's Disease Pathology by Restoring Wnt/β-Catenin Signaling Cascade: an In Vitro Study.
Suresh S; Vellapandian C
Mol Neurobiol; 2024 Apr; 61(4):2064-2080. PubMed ID: 37843801
[TBL] [Abstract][Full Text] [Related]
8. A Novel Inhibitor of DKK1/LRP6 Interactions Against the Alzheimer Disease: An Insilco Approach.
Prajapat M; Singh H; Chaudhary G; Sarma P; Kaur G; Prakash Patel A; Medhi B
Bioinform Biol Insights; 2023; 17():11779322231183762. PubMed ID: 37424708
[TBL] [Abstract][Full Text] [Related]
9. Guanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer's disease.
Liu H; Luo K; Luo D
Sci Rep; 2018 Feb; 8(1):2759. PubMed ID: 29426890
[TBL] [Abstract][Full Text] [Related]
10. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease.
Liu CC; Tsai CW; Deak F; Rogers J; Penuliar M; Sung YM; Maher JN; Fu Y; Li X; Xu H; Estus S; Hoe HS; Fryer JD; Kanekiyo T; Bu G
Neuron; 2014 Oct; 84(1):63-77. PubMed ID: 25242217
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective Potential of Novel Multi-Targeted Isoalloxazine Derivatives in Rodent Models of Alzheimer's Disease Through Activation of Canonical Wnt/β-Catenin Signalling Pathway.
Machhi J; Sinha A; Patel P; Kanhed AM; Upadhyay P; Tripathi A; Parikh ZS; Chruvattil R; Pillai PP; Gupta S; Patel K; Giridhar R; Yadav MR
Neurotox Res; 2016 May; 29(4):495-513. PubMed ID: 26797524
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of PPP(S/T)P motif of the free LRP6 intracellular domain is not required to activate the Wnt/beta-catenin pathway and attenuate GSK3beta activity.
Beagle B; Mi K; Johnson GV
J Cell Biochem; 2009 Nov; 108(4):886-95. PubMed ID: 19711366
[TBL] [Abstract][Full Text] [Related]
13. Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy.
Sai Varshini M; Aishwarya Reddy R; Thaggikuppe Krishnamurthy P
J Drug Target; 2024 Jun; ():1-9. PubMed ID: 38838023
[TBL] [Abstract][Full Text] [Related]
14. Deficient Wnt Signaling and Synaptic Vulnerability in Alzheimer's Disease: Emerging Roles for the LRP6 Receptor.
Buechler J; Salinas PC
Front Synaptic Neurosci; 2018; 10():38. PubMed ID: 30425633
[TBL] [Abstract][Full Text] [Related]
15. Icariin ameliorates glycolytic dysfunction in Alzheimer's disease models by activating the Wnt/β-catenin signaling pathway.
Liu J; Wei AH; Liu TT; Ji XH; Zhang Y; Yan F; Chen MX; Hu JB; Zhou SY; Shi JS; Jin H; Jin F
FEBS J; 2024 May; 291(10):2221-2241. PubMed ID: 38400523
[TBL] [Abstract][Full Text] [Related]
16. Role of multi-targeted bioactive natural molecules and their derivatives in the treatment of Alzheimer's disease: an insight into structure-activity relationship.
Halder D; Das S; R S J; Joseph A
J Biomol Struct Dyn; 2023 Dec; 41(20):11286-11323. PubMed ID: 36579430
[TBL] [Abstract][Full Text] [Related]
17. Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimer's Disease.
Folke J; Pakkenberg B; Brudek T
Mol Neurobiol; 2019 Feb; 56(2):873-891. PubMed ID: 29804228
[TBL] [Abstract][Full Text] [Related]
18. Functional Characterization of a Small-Molecule Inhibitor of the DKK1-LRP6 Interaction.
Iozzi S; Remelli R; Lelli B; Diamanti D; Pileri S; Bracci L; Roncarati R; Caricasole A; Bernocco S
ISRN Mol Biol; 2012; 2012():823875. PubMed ID: 27398238
[TBL] [Abstract][Full Text] [Related]
19. Selenomethionine promoted hippocampal neurogenesis via the PI3K-Akt-GSK3β-Wnt pathway in a mouse model of Alzheimer's disease.
Zheng R; Zhang ZH; Chen C; Chen Y; Jia SZ; Liu Q; Ni JZ; Song GL
Biochem Biophys Res Commun; 2017 Mar; 485(1):6-15. PubMed ID: 28109879
[TBL] [Abstract][Full Text] [Related]
20. A novel high-content imaging-based technique for measuring binding of Dickkopf-1 to low-density lipoprotein receptor-related protein 6.
Priestley RS; Cheung J; Murphy EJ; Ehebauer MT; Davis JB; Di Daniel E
J Pharmacol Toxicol Methods; 2019; 95():47-55. PubMed ID: 30476623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
